Last reviewed 2026-04-20 · How we verify

Reactivan (FENCAMFAMIN)

Phase 2 active Small molecule

Reactivan (generic name: FENCAMFAMIN) is a fencamfamin drug. It is currently in Phase 2 development.

Reactivan is thought to work by increasing the release of certain neurotransmitters in the brain.

Reactivan (FENCAMFAMIN) is a small molecule drug in the fencamfamin class, but information on its target and mechanism of action is limited. Its commercial status and approved indications are also unknown. As a result, there is limited information available on its safety profile and pharmacokinetic properties. Further research is needed to fully understand Reactivan's potential therapeutic applications and risks. Its current owner and development status are also unclear.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	FENCAMFAMIN
Drug class	fencamfamin
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

This means that it may help improve mood and cognitive function by enhancing communication between brain cells. However, the exact details of how it achieves this are not well understood.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Reactivan CI brief — competitive landscape report
Reactivan updates RSS · CI watch RSS

Frequently asked questions about Reactivan

What is Reactivan?

Reactivan (FENCAMFAMIN) is a fencamfamin drug.

How does Reactivan work?

Reactivan is thought to work by increasing the release of certain neurotransmitters in the brain.

What is the generic name of Reactivan?

FENCAMFAMIN is the generic (nonproprietary) name of Reactivan.

What drug class is Reactivan in?

Reactivan belongs to the fencamfamin class. See all fencamfamin drugs at /class/fencamfamin.

What development phase is Reactivan in?

Reactivan is in Phase 2.

Drug class: All fencamfamin drugs
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing